Clinical trial
TART - Troglitazone Atherosclerosis Regression Trial
NCT00116545 · Parke-Davis, Industry · Completed
Key facts
| NCT number | NCT00116545 |
|---|---|
| Title | TART - Troglitazone Atherosclerosis Regression Trial |
| Official title | TART - Troglitazone Atherosclerosis Regression Trial |
| Lead sponsor | Parke-Davis, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Atherosclerosis, Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | troglitazone |
| Enrollment | 288 |
| Start date | Jan 1, 1997 |
| Primary completion | Apr 1, 2000 |
| Completion | Apr 1, 2000 |
| First posted | Jun 30, 2005 |
| Last update posted | Dec 11, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: